Investor Sectoral Asset Management Inc
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Sectoral Asset Management Inc . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2025-02-14 13G/A CTNM / Contineum Therapeutics, Inc. 950,886 950,786
2024-11-14 13G CTNM / Contineum Therapeutics, Inc. 950,886
2024-02-14 13G/A GRTX / Galera Therapeutics, Inc. 1,666,666 0
2024-02-14 13G/A EFTR / eFFECTOR Therapeutics, Inc. 2,382,644 2,382,644
2023-02-13 13G/A EFTR / eFFECTOR Therapeutics, Inc. 2,382,744 2,382,644
2023-02-13 13G GRTX / Galera Therapeutics, Inc. 1,666,666
2022-02-11 13G EFTR / eFFECTOR Therapeutics, Inc. 2,382,744
2021-02-12 13G/A APRE / Aprea Therapeutics, Inc. 1,470,339 163,681
2020-02-13 13G APRE / Aprea Therapeutics, Inc. 1,470,339
2020-02-13 13G/A LJPC / La Jolla Pharmaceutical Co. 1,759,171 0
2019-02-13 13G LJPC / La Jolla Pharmaceutical Co. 1,759,171
2018-02-13 13G/A COLL / Collegium Pharmaceutical, Inc. 2,104,756 1,426,862
2017-02-10 13G/A FOLD / Amicus Therapeutics, Inc. 7,973,436 5,100,198
2017-02-10 13G/A ADXS / Ayala Pharmaceuticals, Inc. 1,790,715 690,074
2017-02-10 13G COLL / Collegium Pharmaceutical, Inc. 2,104,756
2016-02-12 13G/A FOLD / Amicus Therapeutics, Inc. 7,973,436
2016-02-12 13G ADXS / Ayala Pharmaceuticals, Inc. 1,790,715
2016-02-12 13G/A OMED / OptMed Inc
2015-02-13 13G/A IRWD / Ironwood Pharmaceuticals, Inc.
2015-02-13 13G OMED / OptMed Inc 1,598,293
2015-02-13 13G FOLD / Amicus Therapeutics, Inc. 4,765,498
2014-02-12 13G/A SQNM / Sequenom, Inc. 0
2014-02-11 13G/A ITMN / 0
2014-02-11 13G IRWD / Ironwood Pharmaceuticals, Inc. 5,084,999
2014-02-11 13G/A INCY / Incyte Corporation 1,185,260
2013-05-09 13G/A AVEO / AVEO Pharmaceuticals Inc 1,297,006
2013-03-12 13G AVEO / AVEO Pharmaceuticals Inc 5,185,162
2013-02-14 13G/A ITMN / 5,410,922
2013-02-14 13G/A GIVN / Given Imaging Ltd 1,182,214
2013-02-14 13G/A SQNM / Sequenom, Inc. 9,215,967
2013-02-14 13G/A NSPH / Nanosphere, Inc. 0
2013-02-14 13G/A OPTR / Optimer Pharmaceuticals Inc 597,727
2013-02-14 13G/A SSRX / 3sbio Inc. 919,267
2013-02-14 13G/A SVNTQ / Savient Pharmaceuticals Inc 0
2013-02-14 13G INCY / Incyte Corporation 7,862,619
2013-02-14 13G/A ARIA / ARIAD Pharmaceuticals, Inc. 4,000,258
2012-04-10 13G/A ITMN / 6,542,252
2012-02-17 13G SSRX / 3sbio Inc. 1,400,913
2012-02-14 13G/A UTHR / United Therapeutics Corporation 1,835,178
2012-02-14 13G/A NSPH / Nanosphere, Inc. 2,676,744
2012-02-14 13G/A ONXX / Onyx Pharmaceuticals Inc 2,900,521
2012-02-14 13G/A MDVN / Medivation, Inc. 780,255
2012-02-14 13G/A US55027E1029 / Luminex Corporation 1,040,833
2012-02-14 13G/A ITMN / 5,738,237
2012-02-14 13G/A XNPT / XenoPort, Inc. 0
2012-02-14 13G/A GIVN / Given Imaging Ltd 1,521,194
2012-02-14 13G OPTR / Optimer Pharmaceuticals Inc 3,091,355
2012-02-14 13G/A SVNTQ / Savient Pharmaceuticals Inc 5,749,190
2012-02-14 13G/A US00163U1060 / AMAG Pharmaceuticals, Inc. 0
2012-02-14 13G ARIA / ARIAD Pharmaceuticals, Inc. 8,972,258